Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Alcayaga Miranda, Francisca ^a,b   Cuenca, Jimena ^a,b   Martin, Aldo ^a   Contreras, Luis ^a   Figueroa, Fernando E ^a   Khoury, Maroun ^a,b,c  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b Chilean Consortium for Regenerative Medicine   (Chile)

^c Clínica Universidad de Los Andes ^*  (Chile)

Author keywords

MenSCs; Menstrual stem cells; Mesenchymal stems cells; Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMYLASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOKINE; ENROFLOXACIN; GLUCOSE; HEPCIDIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; AUTACOID; CONDITIONED MEDIUM;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BLOOD SAMPLING; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MENSTRUAL DERIVED MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SURVIVAL; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL CULTURE; CONDITIONED MEDIUM; CYTOLOGY; DISEASE MODEL; DOWN REGULATION; FEMALE; MENSTRUATION; MESENCHYMAL STROMA CELL; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; COMBINED MODALITY THERAPY; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HEPCIDINS; HUMANS; INFLAMMATION MEDIATORS; MENSTRUATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; SEPSIS;

EID: 84944388066     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-015-0192-0     Document Type: Article

References (43)

1. Hall SR, Tsoyi K, Ith B, Padera RF, Lederer JA, Wang Z, et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: The importance of neutrophils. Stem Cells. 2013;31:397-407.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54.
3. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42-9.
4. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-91.
5. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047-57.
6. Kim H, Darwish I, Monroy M-F, Prockop DJ, Liles WC, Kain KC. Mesenchymal stromal (stem) cells suppress pro-inflammatory cytokine production but fail to improve survival in experimental staphylococcal toxic shock syndrome. BMC Immunol. 2014;15:1.
7. Tyndall A, Pistoia V. Mesenchymal stem cells combat sepsis. Nat Med. 2009;18-20.
8. Noël D, Djouad F, Bouffi C, Mrugala D, Jorgensen C. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma. 2007;48:1283-9.
9. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-41.
10. Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929-39.
11. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K, et al. Action at a distance: Systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF- stimulated gene/protein 6. Stem Cells. 2011;29:1572-9.
12. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26:151-62.
13. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee J-W, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28:2229-38.
14. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee J-W, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. AJP Lung Cell Mol Physiol. 2012;302:L1003-13.
15. Anderson P, Souza-Moreira L, Morell M, Caro M, O'Valle F, Gonzalez-Rey E, et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut. 2012;1131-1141.
16. Elman JS, Li M, Wang F, Gimble JM, Parekkadan B. A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm (Lond). 2014;11:1.
17. Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582-91.
18. Khoury M, Alcayaga-Miranda F, Illanes SE, Figueroa FE. The promising potential of menstrual stem cells for antenatal diagnosis and cell therapy. Front Immunol. 2014;5:205.
19. Alcayaga-Miranda F, Cuenca J, Luz-Crawford P, Aguila-Díaz C, Fernandez A, Figueroa FE, et al. Characterization of menstrual stem cells: angiogenic effect, migration and hematopoietic stem cell support in comparison with bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2015;6:32.
20. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009;4:31-6.
21. Livak KJ, Livak KJ, Schmittgen TD, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
22. Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010;Fig 1:10-2.
23. Chaston TB, Matak P, Pourvali K, Srai SK, McKie AT, Sharp PA. Hypoxia inhibits hepcidin expression in HuH7 hepatoma cells via decreased SMAD4 signaling. Am J Physiol Cell Physiol. 2011;300:C888-95.
24. Peralta G, Sánchez MB, Garrido JC, Ceballos B, Mateos F, De Benito I, et al. Altered blood glucose concentration is associated with risk of death among patients with community-acquired Gram-negative rod bacteremia. BMC Infect Dis. 2010;10:181.
25. Ceciliani F, Giordano A, Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett. 2002;9:211-23.
26. Fulop AK. Genetics and genomics of hepatic acute phase reactants: a mini-review. Inflamm Allergy Drug Targets. 2007;6:109-15.
27. Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, et al. Increased vascular permeability: A major cause of hypoalbuminaemia in disease and injury. Lancet. 1985;1:781-4.
28. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599-610.
29. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106:16357-62.
30. Hotchkiss RS, Karl IE. The Pathophysiology and Treatment of Sepsis. N Engl J Med. 2003;348:138-50.
31. Fullerton JN, O'Brien AJ, Gilroy DW. Pathways mediating resolution of inflammation: When enough is too much. J Pathol. 2013;231:8-20.
32. Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med. 2007;5:57.
33. Toyoda M, Cui C, Umezawa A. Myogenic transdifferentiation of menstrual blood-derived cells. Acta Myol. 2007;26:176-8.
34. Borlongan CV, Kaneko Y, Maki M, Yu S-J, Ali M, Allickson JG, et al. Menstrual blood cells display stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem Cells Dev. 2010;19:439-52.
35. Khanjani S, Khanmohammadi M, Zarnani AH, Akhondi MM, Ahani A, Ghaempanah Z, et al. Comparative evaluation of differentiation potential of menstrual blood- Versus bone marrow- derived stem cells into hepatocyte-like cells. PLoS One. 2014;9.
36. Lv Y, Xu X, Zhang B, Zhou G, Li H, Du C, Han H: Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice. 2014:1-11.
37. Kusadasi N, Groeneveld ABJ. A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis. Shock. 2013;40:352-7.
38. Lombardo E. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;7:368.
39. Sonnweber T, Nachbaur D, Schroll A, Nairz M, Seifert M, Demetz E, et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut. 2014;63:1-9.
40. Ravasi G, Pelucchi S, Greni F, Mariani R, Giuliano A, Parati G, et al. Circulating factors are involved in hypoxia-induced hepcidin suppression. Blood Cells Mol Dis. 2014;53:204.
41. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007;4, e269.
42. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction. J Am Coll Cardiol. 2009;54:2277-86.
43. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-19.